Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The $517.1M market capitalization puts ZURA squarely in small-cap range for its industry. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Market Cap
$517.1M
Beta
-0.04
P/E (TTM)
—
P/E (Fwd)
-9.85
EPS (TTM)
$-1.13
EPS (Fwd)
$-0.55
ROE
-41.0%
ROA
-25.4%
Cash
$225.6M
Total Debt
$0
Free CF
-$46.9M
52W Change
185.3%
Annual Financials
Cash vs Debt
Zura Bio Limited reports $225.6M in cash and $0 in total debt. Free cash flow is running at -$46.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -41.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Zura Bio Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZURA.